Controlling release from 3D printed medical devices using CLIP and drug-loaded liquid resins

JOURNAL OF CONTROLLED RELEASE

卷:278

Article

Bloomquist, Cameron J.¹  Mecham, Michael B.²  Paradzinsky, Mark D.²  Janusziewicz, Rima³  Warner, Samuel B.^1,4,5  Luft, J. Christopher^1,2  Mecham, Sue J.²  Wang, Andrew Z.^2,6  DeSimone, Joseph M.^{1,2,3,4,5,7,8} 

[1] Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Chapel Hill, NC 27599 USA

[2] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Inst Nanomed, Chapel Hill, NC 27599 USA

[3] Univ North Carolina Chapel Hill, Dept Chem, Chapel Hill, NC 27599 USA

[4] Univ North Carolina Chapel Hill, Joint Dept Biomed Engn, Chapel Hill, NC 27599 USA

[5] North Carolina State Univ, Chapel Hill, NC 27599 USA

[6] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA

[7] North Carolina State Univ, Dept Chem & Biomed Engn, Raleigh, NC 27695 USA

[8] Carbon, Redwood City, CA 94063 USA

关键词: Continuous Liquid Interface Production;    3D printing;    Additive manufacturing;    Drug delivery;    Crosslink density;    Medical device;   

DOI  :  10.1016/j.jconrel.2018.03.026

来源: Elsevier

【 摘 要 】

Mass customization along with the ability to generate designs using medical imaging data makes 3D printing an attractive method for the fabrication of patient-tailored drug and medical devices. Herein we describe the application of Continuous Liquid Interface Production (CLIP) as a method to fabricate biocompatible and drug-loaded devices with controlled release properties, using liquid resins containing active pharmaceutical ingredients (API). In this work, we characterize how the release kinetics of a model small molecule, rhodamine B-base (RhB), are affected by device geometry, network crosslink density, and the polymer composition of polycaprolactone- and poly (ethylene glycol)-based networks. To demonstrate the applicability of using API-loaded liquid resins with CLIP, the UV stability was evaluated for a panel of clinically-relevant small molecule drugs. Finally, select formulations were tested for biocompatibility, degradation and encapsulation of docetaxel (DTXL) and dexamethasone-acetate (DexAc). Formulations were shown to be biocompatible over the course of 175 days of in vitro degradation and the clinically-relevant drugs could be encapsulated and released in a controlled fashion. This study reveals the potential of the CLIP manufacturing platform to serve as a method for the fabrication of patient-specific medical and drug-delivery devices for personalized medicine.

【 授权许可】

Free